Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsShionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease PortfolioShionogi plans to acquire IntraBio for $2 billion, adding AQNEURSA and expanding its rare neurological disease portfolio. Written By: Rishabh…Fact-Checked
Mergers & AcquisitionsAlector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therapy AL050Alector has granted Genentech worldwide rights to its preclinical AL050 GCase enzyme replacement therapy for Parkinson’s disease.Fact-Checked
Mergers & AcquisitionsCSL and Alentis Partner to Advance Lixudebart in Kidney and Liver DiseasesCSL and Alentis have entered a global collaboration to advance lixudebart, an investigational claudin-1 antibody, across rare kidney and liver diseases, including AAV-RPGN, FSGS and PSC.Fact-Checked
Mergers & AcquisitionsSernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s Type 1 Diabetes Cell Therapy ProgramsSernova and Seraxis have closed an $11.2 million financing to advance SR-02, an allogeneic stem cell-derived pancreatic islet cell therapy for type 1 diabetes, with Phase 1/2 dosing…Fact-Checked
Mergers & AcquisitionsAbogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203Abogen Biosciences and Novartis have entered a licensing and option agreement covering ABO2203, an investigational mRNA-encoded CD19×CD3 T-cell engager for autoimmune diseases, along with additional RNA programs.Fact-Checked
Mergers & AcquisitionsItalfarmaco, JCR Sign JR-141 Licensing Deal for Hunter SyndromeItalfarmaco and JCR Pharmaceuticals have signed an exclusive licensing agreement for JR-141 (pabinafusp alfa), an investigational blood-brain barrier-penetrating enzyme replacement therapy being evaluated for Hunter syndrome in a…Fact-Checked
Mergers & AcquisitionsRegeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting AntibodiesRegeneron and Sanofi have expanded their global antibody collaboration to include four next-generation, long-acting immunology antibodies targeting key type 2 inflammation pathways.Fact-Checked
Mergers & AcquisitionsAstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC CombinationsAstraZeneca is investing $2 billion in Summit Therapeutics and will sponsor clinical trials combining ivonescimab with Sone-Ve, a CLDN18.2-targeting ADC, in gastrointestinal cancers.Fact-Checked
Mergers & AcquisitionsNovo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonist HRS-1596Novo Nordisk has licensed global rights outside Greater China to Hengrui Pharma’s HRS-1596, a phase 1-ready oral GLP-1/GIP dual receptor agonist with potential once-weekly dosing.Fact-Checked
Mergers & AcquisitionsMerck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015Merck has entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral molecular glue inhibitor targeting KRAS G12D in its active (ON) state.Fact-Checked
Mergers & AcquisitionsHenlius, Amberstone Develop Tumor-Activated TCEs for Solid TumorsShanghai Henlius and Amberstone Biosciences have entered a global licensing agreement to develop conditionally activated T-cell engagers against up to two tumor-associated antigens.Fact-Checked
Mergers & AcquisitionsAtavistik Bio, Roche Partner on Allosteric CVRM DrugsAtavistik Bio and Roche have entered a strategic research collaboration to discover novel allosteric small molecules for cardiovascular, renal, and metabolic diseases.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.